This highlights that plasma p-tau may be one of the earliest biomarkers to change in AD, and it continues to reflect Aβ pathology whilst also giving additional information on the progression of tau pathology up to 10 years before tau PET positivity is detected (Bateman et al., 2012). Here, MAPT is linked to Alzheimer disease.